| 1 |
Autologous Ex-vivo Gene Modified HSCT in MPSII |
Mucopolysaccharidosis II |
Genetic: Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII |
University of Manchester|AVROBIO|CTI Clinical Trial and Consulting Services|Great Ormond Street Hospital for Children NHS Foundation Trust|Manchester University NHS Foundation Trust |
Phase 1|Phase 2 |
NCT05665166 |
2023-06-01 |
| 2 |
Personalized Medicine for Advanced Biliary Cancer Patients |
Biliary Tract Neoplasms |
Drug: Futibatinib|Drug: Ivosidenib|Drug: Zanidatamab|Drug: Trastuzumab|Drug: Neratinib|Drug: Encorafenib|Drug: Binimetinib|Drug: Niraparib|Drug: Cisplatin|Drug: Gemcitabine |
UNICANCER|Cancer Research UK & UCL Cancer Trials Centre|Belgian Group of Digestive Oncology|National Cancer Institute, France|Cancer Research UK|Taiho Oncology, Inc.|Servier|Zymeworks Inc.|Accord Healthcare, Inc.|Pierre Fabre Medicament|GlaxoSmithKline Research & Development Limited |
Phase 3 |
NCT05615818 |
2023-06-01 |
| 3 |
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: ABBV-383 |
TeneoOne Inc. |
Phase 1 |
NCT05650632 |
2023-03-21 |
| 4 |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
Primary Immune Thrombocytopenia (ITP) |
Biological: Ianalumab|Drug: Placebo|Drug: Corticosteroids |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05653349 |
2023-03-06 |
| 5 |
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma |
Diffuse Large B Cell Lymphoma |
Biological: Epcoritamab|Drug: Lenalidomide |
Genmab|AbbVie |
Phase 2 |
NCT05660967 |
2023-03-06 |
| 6 |
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) |
Alzheimer's Disease |
Biological: IBC-Ab002|Other: Placebo |
Immunobrain Checkpoint|National Institute on Aging (NIA)|Alzheimer's Association |
Phase 1 |
NCT05551741 |
2023-02-23 |
| 7 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma |
Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone |
AbbVie|Genmab |
Phase 3 |
NCT05578976 |
2023-02-08 |
| 8 |
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids |
Primary Immune Thrombocytopenia |
Biological: Ianalumab|Drug: Eltrombopag|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05653219 |
2023-02-02 |
| 9 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF |
Idiopathic Pulmonary Fibrosis |
Biological: CHF10067 starting dose|Biological: CHF10067 intermediate dose|Biological: CHF10067 high dose|Drug: Placebo |
Chiesi Farmaceutici S.p.A. |
Phase 1 |
NCT05513950 |
2023-01-25 |
| 10 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) |
Biological: Ianalumab|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05648968 |
2022-12-30 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.